RE:RE:RE:Durable Response Hi Eoganacht...
Maybe you can clarify the discrepancy I'm seeing in the 450 day CR data when comparing the 41 total patients (which includes 2 CRs from Ph 1b) & the first 20 treated in Ph2 as presented in the MD&A from May. Looking at the 41 patient chart, there are a total of 5 CRs at 450 days (2 CRs from Ph 1b + 3 CRs from Ph 2). Yet, according to the chart representing the first 20 treated in Ph 2, there are also 5 CRs = the reported 25% CR rate. If this is the case, for the 41 patient chart, should they not have then reported 7 CRs instead of 5 at 450 days (5 from Ph 2 + 2 from Ph 1b) with 17 pending....rather than the reported 5 CRs with 19 pending?
With the above scenario, however, we wouldn't be able to decipher how many of the initial 3 CRs from the first 12 were able to maintain a CR at 450 days. But even if all of the initial 3 maintained CR at 450 days, the worse to best case scenario re: the 450 day CR rate for the 8 fully optimized (of the first 20 treated) would be 25% to 63%...with the lower end still beating Keytruda by 6 percentage points.